These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23294895)

  • 1. Aspirin and aspirin resistance in coronary artery disease.
    Kasmeridis C; Apostolakis S; Lip GY
    Curr Opin Pharmacol; 2013 Apr; 13(2):242-50. PubMed ID: 23294895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease.
    Larsen SB; Grove EL; Neergaard-Petersen S; Würtz M; Hvas AM; Kristensen SD
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28780510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet effect of aspirin in patients with coronary artery disease.
    Grove EL
    Dan Med J; 2012 Sep; 59(9):B4506. PubMed ID: 22951204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent.
    Zimmermann N; Gams E; Hohlfeld T
    Eur J Cardiothorac Surg; 2008 Jul; 34(1):93-108. PubMed ID: 18448350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease.
    Thompson PL; Verheugt FW
    Clin Ther; 2014 Sep; 36(9):1176-81. PubMed ID: 25234549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current evidence and clinical implications of aspirin resistance.
    Kasotakis G; Pipinos II; Lynch TG
    J Vasc Surg; 2009 Dec; 50(6):1500-10. PubMed ID: 19679423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotics in atrial fibrillation and coronary disease.
    Velagapudi P; Turagam MK; Agrawal H; Mittal M; Kocheril AG; Aggarwal K
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):977-86. PubMed ID: 25046150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin and clopidogrel response variability: review of the published literature.
    Ferguson AD; Dokainish H; Lakkis N
    Tex Heart Inst J; 2008; 35(3):313-20. PubMed ID: 18941611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of aspirin for primary prevention of cardiovascular events in diabetic patients--is it justified?].
    Benhamou Y; Lévesque H
    Rev Med Interne; 2009 Dec; 30(12):1001-3. PubMed ID: 19833416
    [No Abstract]   [Full Text] [Related]  

  • 10. A mainstay drug underperforms. But a bedside test makes it easier to spot "aspirin resistance".
    Heart Advis; 2004 Aug; 7(8):3. PubMed ID: 15551431
    [No Abstract]   [Full Text] [Related]  

  • 11. Aspirin in coronary artery disease: an appraisal of functions and limitations.
    Würtz M
    Dan Med J; 2015 Apr; 62(4):B5011. PubMed ID: 25872543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adherence to antiplatelet therapy in patients with coronary artery disease].
    Legrand D; Legrand V
    Rev Med Liege; 2010; 65(5-6):304-10. PubMed ID: 20684411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry).
    Cannon CP; Rhee KE; Califf RM; Boden WE; Hirsch AT; Alberts MJ; Cable G; Shao M; Ohman EM; Steg PG; Eagle KA; Bhatt DL;
    Am J Cardiol; 2010 Feb; 105(4):445-52. PubMed ID: 20152237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    Lopes RD; Rao M; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Hylek EM; Kowey P; Piccini JP; Singer DE; Chang P; Peterson ED; Mahaffey KW
    Am J Med; 2016 Jun; 129(6):592-599.e1. PubMed ID: 26797080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study.
    Karolczak K; Kamysz W; Karafova A; Drzewoski J; Watala C
    Pharmacol Res; 2013 Aug; 74():7-22. PubMed ID: 23665469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy.
    Ben-Dor I; Kleiman NS; Lev E
    Am J Cardiol; 2009 Jul; 104(2):227-33. PubMed ID: 19576352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antiplatelet drugs in prevention and treatment of coronary heart disease: aspirin is obligatory, quite sufficient, and safe].
    Averkov OV
    Kardiologiia; 2003; 43(6):77-83. PubMed ID: 13677327
    [No Abstract]   [Full Text] [Related]  

  • 18. Aspirin resistance: current status and role of tailored therapy.
    Grinstein J; Cannon CP
    Clin Cardiol; 2012 Nov; 35(11):673-81. PubMed ID: 22740110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of laboratory detection methods of aspirin resistance in coronary artery disease patients.
    Kim KE; Woo KS; Goh RY; Quan ML; Cha KS; Kim MH; Han JY
    Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):50-5. PubMed ID: 19016915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspirin resistance, an emerging, often overlooked, factor in the management of patients with coronary artery disease.
    Makaryus AN
    Clin Cardiol; 2006 Apr; 29(4):144-8. PubMed ID: 16649722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.